EICHOR
● Terminated
Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies
Condition: Healthy (For Part A) · Chronic Myeloid Leukemia (for Part B and C) · Sponsor: Sun Pharma Advanced Research Company Limited
About this study
Phase 1/2 study to determine safety, tolerability, pharmacokinetics, and anti-leukemic activity of Vodobatinib (K0706) in treatment-refractory/intolerant CML
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (35)
| The Oncology Institute of Hope and Innovation, Innovative Clinical Research Institute | Downey, California, United States | — |
| UCLA Hematologic Malignancy Program | Los Angeles, California, United States | — |
| Mayo Clinic | Jacksonville, Florida, United States | — |
| Board of Regents of the University System of Georgia | Augusta, Georgia, United States | — |
| Memorial Sloan Kettering Cancer Center - MAIN | New York, New York, United States | — |
| Baylor University Medical Center | Dallas, Texas, United States | — |
| MD Anderson Cancer Center | Houston, Texas, United States | — |
| Huntsman Cancer Institute University of Utah | Salt Lake City, Utah, United States | — |
| Cliniques Universitaires Saint-Luc | Brussels, Belgium | — |
| Institut Paoli Calmettes | Marseille, Bouches-du-Rhône, France | — |
| Centre Léon Bérard | Lyon, Rhone, France | — |
| Centre Hospitalier Lyon Sud | Pierre-Bénite, Rhone, France | — |
+ 23 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02629692